Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2023.08.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort.
Alzheimers Dement
December 2024
Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
Background: Diagnosing sporadic early‐onset AD (EOAD, age‐at‐onset<65) is challenging: in the multi‐center Longitudinal Early‐onset Alzheimer’s Disease Study, ∼25% of patients with clinically diagnosed EOAD are amyloid‐PET‐negative. Here we used FDG‐PET to characterize the heterogeneity of hypometabolic profiles in these patients and better identify underlying etiologies.
Method: Seventy‐four amyloid‐PET‐negative patients with clinical diagnosis of sporadic EOAD (MCI or mild dementia stage) underwent FDG‐PET.
Biomarker Evaluation in Young Onset Dementia from Diverse Populations.
Alzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, San Francisco, CA, USA
Background: Early onset dementia (EOD) affects people at the peak of their personal and professional responsibilities and economic productivity. Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD) are the most common EOD etiologies in Non‐Latinx White adults (NLW). Black and Latinx older adults bear a disproportionate burden of dementia compared to NLW, likely due to vulnerabilities that confer increased risk, such as cardiovascular factors, socioeconomic stressors, and structural racism.
View Article and Find Full Text PDFHuman iPSC‐derived neuron modeling for the study of early‐onset Alzheimer’s disease.
Alzheimers Dement
December 2024
Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA
Background: Early‐onset Alzheimer’s disease (EOAD) is a complex disease that occurs at an early age at onset (AAO) before 65 years, constituting 5‐6% of all AD cases and remains poorly understood. Patient‐derived induced pluripotent stem cells (iPSCs) have been used to model different forms of EOAD that display heterogeneous disease mechanisms.
Method: We examined iPSC‐derived neurons from both familial EOAD harboring mutations in , and non‐familial EOAD patients at an early AAO.
Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort.
Alzheimers Dement
December 2024
Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
Background: Diagnosing sporadic early‐onset AD (EOAD, age‐at‐onset<65) is challenging: in the multi‐center Longitudinal Early‐onset Alzheimer’s Disease Study, ∼25% of patients with clinically diagnosed EOAD are amyloid‐PET‐negative. Here we used FDG‐PET to characterize the heterogeneity of hypometabolic profiles in these patients and better identify underlying etiologies.
Method: Seventy‐four amyloid‐PET‐negative patients with clinical diagnosis of sporadic EOAD (MCI or mild dementia stage) underwent FDG‐PET.
Unraveling the Link Between SGLT2 Inhibition, Circulating Metabolites, and Alzheimer’s Dementia: A Mendelian Randomization Study.
Alzheimers Dement
December 2024
Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China;, Beijing, China
Background: Individuals with type 2 diabetes mellitus (T2DM) face an increased risk of dementia. Recent discoveries indicate that SGLT2 inhibitors, a newer class of anti‐diabetic medication, exhibit beneficial metabolic effects beyond glucose control, offering a potential avenue for mitigating the risk of Alzheimer’s disease (AD). However, limited evidence exists regarding whether the use of SGLT2 inhibitors effectively reduces the risk of AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!